Exelixis
EXEL
#1724
Rank
NZ$21.40 B
Marketcap
NZ$85.16
Share price
-0.34%
Change (1 day)
17.56%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2026 (TTM): NZ$5.35

According to Exelixis's latest financial reports the company's current EPS (TTM) is NZ$5.33. In 2025 the company made an earnings per share (EPS) of NZ$4.92.

EPS history for Exelixis from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$5.358.73%
2025NZ$4.92
2023NZ$1.1114.61%
2022NZ$0.97-22.97%
2021NZ$1.26100%
2020NZ$0.63-65.09%
2019NZ$1.81-53.91%
2018NZ$3.92333.96%
2017NZ$0.90-260.61%
2016NZ-$0.56-58.75%
2015NZ-$1.36-42.45%
2014NZ-$2.375.3%
2013NZ-$2.25

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
NZ$14.89 179.12%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
NZ$2.23-58.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$24.67 362.62%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
NZ$4.36-18.22%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
NZ$6.06 13.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$6.07 13.74%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
NZ$6.62 24.16%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
NZ-$6.25-217.25%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
NZ-$1.43-126.84%๐Ÿ‡บ๐Ÿ‡ธ USA